Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics

Resistance to anti-tumor therapeutics is an important clinical problem. Tumor-targeted therapies currently used in the clinic are derived from antibodies or small molecules that mitigate growth factor activity. These have improved therapeutic efficacy and safety compared to traditional treatment mod...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Control Release
Autori principali: Sims, Jessica D., Taguiam, Jan Michael, Alonso-Valenteen, Felix, Markman, Janet, Agadjanian, Hasmik, Chu, David, Lubow, Jay, Abrol, Ravinder, Srinivas, Dustin, Jain, Anjali, Han, Bingchen, Qu, Ying, Mirzadehgan, Parisa, Hwang, Jae-Youn, Rentsendorj, Altan, Chung, Alice, Lester, Jenny, Karlan, Beth Y., Gray, Harry B., Gross, Zeev, Giuliano, Armando, Cui, Xiaojiang, Medina-Kauwe, Lali K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5807213/
https://ncbi.nlm.nih.gov/pubmed/29288681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2017.12.024
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi